MedTrace Logo

COVID-19 and Brain: Cognition and Mental Health

NCT05307549 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-05-30

No results posted yet for this study

Summary

The main goal of DIANA is to investigate the potential discriminative power of multimodal biomarkers in COVID adverse outcomes. The study of the neuropathological underlying mechanisms in COVID from a translational approach at: (1) the behavioural-clinical level from cognitive, emotional and functional data; (2) the brain connectome level from structural and functional imaging data; and (3) biogenetic level from blood and stool data. Moreover, the investigators will develop machine learning based predictive models of cognitive, mental health, functionality, and brain connectivity evolution in post-COVID syndrome patients.

Conditions

Sponsors & Collaborators

  • Consorci Sanitari de Terrassa

    collaborator OTHER

  • Universitat Politècnica de Catalunya

    collaborator OTHER

  • University of Barcelona

    lead OTHER

Principal Investigators

  • Carme Junqué, PhD · University of Barcelona

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-14
Primary Completion
2022-11-30
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307549 on ClinicalTrials.gov